Latest filing published 18 Aug 2026 for BridgeBio Pharma, Inc., €1.6M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Thomas Trimarchi in BridgeBio Pharma, Inc. The record holds 14 filings, for trades running from 6 August 2024 to 16 August 2026.
Every open-market trade on record is a sale: 1 sale worth €1.8M. Other entries cover 13 share grants.
On 18 August 2026 came the latest disclosure, a share grant for €1.6M in BridgeBio Pharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations